Summer 2026

ML Engineer Intern

Updated on 5/21/2026

Pathos

Pathos

51-200 employees

AI-powered platform for oncology drug development

Compensation Overview

$30 - $60/hr

New York, NY, USA

Hybrid

Hybrid role; up to 3 days onsite per week at NYC Headquarters.

Category
AI & Machine Learning (1)
Required Skills
Python
Neural Networks
Pytorch
Machine Learning
Computer Networking
Requirements
  • Strong programming ability in Python
  • Solid fundamentals in machine learning / deep learning through coursework, research, internships, or substantial projects
  • Experience with PyTorch and modern training workflows
  • Comfort operating in ambiguous problem spaces with a bias toward execution
Responsibilities
  • Use Nsight to profile and analyze post-training pipeline, identify process that dominates wall-clock time (rollout GEMM vs KV cache I/O vs weight reloading vs reward compute)
  • Design and prototype an NCCL-based weight broadcast path that streams updated LoRA (and, optionally, full base) weights directly into inference engine’s GPU memory
  • Improve hyper-scale training throughput and efficiency by investigating sharding granularity, mixed-precision policy, communication overlap, gradient bucketing, etc.
  • Deep dive into Mixture-of-Experts training strategies, study how to layout tensor, expert, and data parallel groups on H200 with InfiniBand island. Token vs sequence level routing
  • Design strategies to maintain training stability and load balancing, including aux-loss design, capacity factor, drop/pad policies, router z-loss, expert dropout.
  • Experiment and derive best practice for SFT and RL on top of a pre-trained MoE, router freezing, gradient flow concerns
  • Develop prefill/decode disaggregation serving to decouple long-prompt prefill cost from autoregressive decode loop, deep dive into node replacement, KV cache transfer over NVlink/InfiniBand, scheduling policy, and how to balance pools as load mixes shifts
Desired Qualifications
  • Experience with distributed systems (e.g., multi-node training, large-scale data loaders, cluster scheduling)
  • Familiarity with performance optimization (profiling, kernel efficiency, GPU utilization, throughput/latency)
  • Research experience (papers, preprints, open-source contributions, or significant independent work)
  • Exposure to biomedical, clinical, or multimodal datasets (helpful but not required)

Pathos combines artificial intelligence with oncology to speed up cancer drug development. It analyzes large oncology datasets, including genomics, using advanced AI and machine learning to identify novel therapeutic targets and biomarkers, guiding the creation of more effective, personalized cancer treatments. The company collaborates with pharmaceutical and biotechnology partners to de-risk pipelines, shorten development timelines, and increase the odds of success for new cancer therapies. Pathos differentiates itself by offering an integrated data-driven platform that leverages diverse genomic and clinical data to drive target validation and biomarker discovery for partner programs. Its goal is to accelerate the delivery of better cancer treatments by turning complex data into actionable insights.

Company Size

51-200

Company Stage

Series D

Total Funding

$365M

Headquarters

Chicago, Illinois

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • $365M Series D funding in 2026 values Pathos at $1.6B to expand AI oncology platform.
  • AstraZeneca $200M partnership with Tempus validates PathOS for multimodal oncology model development.
  • Q1 2026 acquisition of DeuterOncology stake creates portfolio returns beyond licensing fees.

What critics are saying

  • Pathios Therapeutics' PTT-4256 GPR65 inhibitor captures immunotherapy market share within 12-24 months.
  • AstraZeneca diverts resources to Tempus-led model, sidelining PathOS within 6-12 months.
  • Pocenbrodib trial underperforms versus abiraterone/olaparib by Q2 2026, exhausting cash reserves.

What makes Pathos unique

  • Pathos AI's PathOS platform integrates multiomic data for biomarker-driven patient selection in mCRPC trials.
  • Foundry platform identified DO-2 MET inhibitor with 100% tumor shrinkage and 5% edema in Phase 1 NSCLC.
  • Pocenbrodib targets novel CBP/p300 proteins to overcome resistance in post-anti-androgen mCRPC patients.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pathos who can refer or advise you

Benefits

Hybrid Work Options

Remote Work Options

401(k) Retirement Plan

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

4%

2 year growth

4%
GlobalData
May 16th, 2025
Pathos AI raises $365m for oncology drug development

Pathos AI has raised $365m in a Series D funding round as it prepares to widen its AI-enabled platform to advance the development of oncology drugs.

The Pharma Letter
May 16th, 2025
Pathos AI lands $365 million for AI-driven cancer drugs

Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a series D financing round, lifting its valuation to about $1.6 billion.

The Manila Times
May 8th, 2025
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) - Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member.

Pharmaceutical Business Review
Apr 25th, 2025
Tempus AI, AstraZeneca, and Pathos AI join forces on cancer care

Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.

GlobalData
Apr 24th, 2025
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery.